Advertisement
Journal Home
Search for

Articles in Press

Return to articles in press list

Impact of the expression of Aurora-A, p53, and Mib-1 on the prognosis of urothelial carcinomas of the upper urinary tract

Sylvia Scarpini, M.D.a, Morgan Rouprêt, M.D., Ph.D.bfCorresponding Author Informationemail address, Raphaële Renard-Penna, M.D.c, Philippe Camparo, M.D.d, Olivier Cussenot, M.D., Ph.D.ef, Eva Compérat, M.D., Ph.D.a

Received 21 October 2009; received in revised form 29 November 2009; accepted 1 December 2009. published online 02 March 2010.
Corrected Proof

Abstract 

Objectives

To investigate whether overexpression of p53, MIB-1, and Aurora-A on protein level played a role in the relapse of urothelial carcinomas of the upper urinary tract (UC-UUT).

Materials and methods

The following data from the files of 42 patients treated for UC-UUT were collated: age, prior history of cancer, tumor stage and grade, and disease progression. Immunohistochemistry (IHC) for p53, MIB-1, and Aurora-A was performed on tissue microarray sections from tumor tissue.

Results

Patients aged 46 to 100 years (mean 70.6 years). Overall, 23 (54%) patients died from progression of UT-UCC. The surgical stage was significantly associated with MIB-1 and Aurora-A overexpression (P = 0.004 for each). Univariate analysis showed that relapse was significantly associated with ureteral localization (P = 0.02), the presence of vascular invasion (VI) (P = 0.003), high grade (P = 0.04), high stage UT-UCCs (P = 0.02), and p53 (P = 0.01), Aurora-A (P = 0.01), and MIB-1 overexpression (P = 0.02). In multivariate analysis, relapse was associated with high grade (P = 0.04), high stage (P = 0.04), VI (P < 0.0001, respectively), and p53 (P = 0.04) and Aurora-A (P = 0.02) overexpression but not with MIB-1 overexpression (P = 0.06). In addition, expressions of p53, MIB-1, and Aurora-A were significantly associated with presence of VI (P = 0.008, P = 0.001, and P = 0.003, respectively).

Conclusion

Aurora-A and p53 are important factors in UC-UUT development and might be useful as independent factors for predicting clinical outcome and presence of VI. Aurora-A seems to influence the development of VI and tumor aggressiveness via a mechanism not clearly elucidated yet.

a Academic Pathology Department, Hôpital La Pitié Salpêtrière, Université Pierre et Marie Curie, Paris, France

b Academic Urology Department, Hôpital La Pitié Salpêtrière, Université Pierre et Marie Curie, Paris, France

c Academic Radiology Department, Hôpital La Pitié Salpêtrière, Université Pierre et Marie Curie, Paris, France

d Pathology Department, Hôpital d'Instructions des Armées Val-de-Grâce, Paris, France

e Academic Urology Department, Hôpital Tenon, Université Pierre et Marie Curie, Paris, France

f CeRePP, Centre d'Etudes et de Recherche sur les Pathologies Prostatiques, University Paris, Paris, France

Corresponding Author InformationCorresponding author. Tel.: +003-3660544166; fax: +003-142177112.

PII: S1078-1439(09)00403-7

doi:10.1016/j.urolonc.2009.12.003